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Abstract
Background: Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting b2-agonist in development for chronic
obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and
tolerability of indacaterol to that of placebo in patients with moderate-to-severe COPD.
Methods: Efficacy variables included 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose) at Week
12 (primary endpoint) and after Day 1, and the percentage of COPD days with poor control (i.e., worsening
symptoms). Safety was assessed by adverse events (AEs), mean serum potassium and blood glucose, QTc
(Fridericia), and vital signs.
Results: Patients were randomised (n = 416, mean age 63 years) to receive either indacaterol 150 μg o.d. (n = 211) or
placebo (n = 205) via a single-dose dry-powder inhaler; 87.5% completed the study. Trough FEV1 (LSM ± SEM) at Week
12 was 1.48 ± 0.018 L for indacaterol and 1.35 ± 0.019 L for placebo, a clinically relevant difference of 130 ± 24 mL
(p < 0.001). Trough FEV1 after one dose was significantly higher with indacaterol than placebo (p < 0.001). Indacaterol
demonstrated significantly higher peak FEV1 than placebo, both on Day 1 and at Week 12, with indacaterol-placebo
differences (LSM ± SEM) of 190 ± 28 (p < 0.001) and 160 ± 28 mL (p < 0.001), respectively. Standardised AUC
measurements for FEV1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all
significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and
170 ± 24 mL, respectively. Indacaterol significantly reduced the percentage of days of poor control versus placebo by
22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001). The overall
rates of AEs were comparable between the groups (indacaterol 49.3%, placebo 46.8%), with the most common AEs
being COPD worsening (indacaterol 8.5%, placebo 12.2%) and cough (indacaterol 6.2%, placebo 7.3%). One patient died
in the placebo group. Serum potassium and blood glucose levels did not differ significantly between the two groups,
and no patient had QTc >500 ms.
Conclusions: Indacaterol 150 μg o.d. provided clinically significant and sustained bronchodilation, reduced rescue
medication use, and had a safety and tolerability profile similar to placebo.
Trial registration: NCT00624286
Background
Current international clinical practice guidelines for
chronic obstructive pulmonary disease (COPD), such as
those from the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) [1], recommend inhaled broncho-
dilators, including b2-agonists and anticholinergics, for
the symptomatic management of COPD, with regular
use of long-acting bronchodilators having been shown
to be more effective and convenient than treatment with
short-acting bronchodilators [2-4]. Currently available
inhaled long-acting b2-agonists (LABAs), such as salme-
terol and formoterol, provide bronchodilation for
approximately 12 h at recommended doses and hence
are administered twice daily [5,6]. In chronic diseases * Correspondence: benjamin.kramer@novartis.com
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improved if the treatment regimens were simplified by
reducing dosing frequency [7].
Indacaterol is a novel, once-daily (o.d.), inhaled LABA
for the treatment of COPD. Indacaterol is a partial ago-
nist at the human b2-adrenoceptor with a similar bind-
ing affinity to the b2 receptor as formoterol and higher
intrinsic activity than salmeterol [8]. In vitro and in vivo
preclinical studies of this compound have already con-
firmed its long duration of action (suitable for o.d. dos-
ing in humans), fast onset of action, and improved
cardiovascular safety profile [8]. Clinical studies of up to
28 days duration have shown that indacaterol has 24-h
bronchodilator efficacy on o.d. dosing, with a good over-
all safety and tolerability profile [9-11].
The objective of this study was to confirm the efficacy
and safety of indacaterol (150 μg), taken o.d. for 12
weeks, in patients with moderate-to-severe COPD.
Methods
Study design
This was a 12-week, multi-centre, double-blind, placebo-
controlled, parallel-group, Phase III study in patients
with moderate-to-severe COPD. The study comprised a
pre-screening period, a 2-week screening/run-in period,
and a 12-week double-blind treatment period. During
the pre-screening visit, patients’ ongoing COPD medica-
tions were reviewed, and if required, patients were
switched from medications prohibited in this study to
an allowed COPD therapy (see the Study treatment sec-
tion). This pre-screening period was followed by a 14-
day run-in period (Visits 1 and 2; Day - 14 to Day 1),
during which the eligibility of patients for the study was
assessed and baseline patient diary data were collected.
The study was conducted in accordance with the
Declaration of Helsinki (1989) and local applicable laws
and regulations. Approval was obtained from the Institu-
tional Review Board or Independent Ethics Committee of
each participating study centre. All patients provided writ-
ten informed consent prior to participating in the study.
Study population
Male and female adults (aged ≥40 years) with a clinical
diagnosis of COPD (GOLD 2005) [12] and a smoking
history of at least 20 pack years were recruited. At Visit
1, patients had to demonstrate a forced expiratory
volume in 1 s (FEV1) of <80% but ≥30% of the predicted
normal value and FEV1/forced vital capacity (FVC) of
<70% within 30 min of inhalation of 400 μgo f
salbutamol.
Patients were excluded if they had any recent respira-
tory tract infection, were hospitalised for a COPD
exacerbation (6 weeks prior to Visit 1 or during the
run-in period), had a history of asthma (indicated by,
but not limited to, blood eosinophil count >400/mm
3 or
onset of respiratory symptoms prior to age 40 years) or
any significant pulmonary disease or cardiovascular
abnormality. The following medications were prohibited
prior to Visit 1 for at least the minimum washout period
(duration is specified within parenthesis) or at any time
during the study: long-acting anticholinergic agents
(7 days), short-acting anticholinergics (8 h), fixed-dose
combination (FDC) of a b2-agonist and an inhaled corti-
costeroid (ICS) (48 h), FDC of a short-acting b2-agonist
and a short-acting anticholinergic (8 h), other LABAs
(48 h), short-acting b2-agonists (other than those pre-
scribed in the study) (6 h), xanthine derivatives
(1 week), and parenteral or oral corticosteroids
(1 month). Patients were also excluded if they were tak-
ing nonselective beta-blocking agents, non-potassium
sparing diuretics, or certain cardiac antiarrhythmics.
Patients on FDCs of a b2-agonist and an ICS were to be
switched to the equivalent ICS prior to the run-in per-
i o d ,w i t ht h ed o s ea n dd o s a g er e g i m e nt or e m a i n
unchanged for the duration of the study.
Study treatment
Randomisation to treatment groups
Following the screening/run-in period, eligible patients
were randomised using validated systems (Visit 3) to
receive double-blind indacaterol 150 μg o.d. or matching
placebo through a single-dose dry-powder inhaler
(SDDPI) for 12 weeks. Randomisation was stratified by
smoking status so that the balance was the same in the
two treatment groups. Patients were instructed to inhale
study medication in the morning (between 08.00 and
11.00 a.m.).
Permitted medications
Salbutamol was permitted as a rescue medication
throughout the study; however, patients were to refrain
from using it within 6 h prior to the study visits. Daily
ICS monotherapy was maintained at a constant dose
and dosage regimen throughout the study in patients
who were previously on ICS or FDC at baseline.
Blinding
Patients, investigators, clinical staff performing assess-
ments, data analysts, and the sponsor’s trial team were
blinded to treatment from the time of randomisation to
database lock (unless there were any patient emergen-
cies). All the study drugs were identical in appearance,
packaging, labelling, and administration schedule.
Study assessments
Spirometry measurements were obtained at screening/
run-in visits to assess patient eligibility (Day - 14). Dur-
ing the double-blind treatment period, patients’ visits to
the clinics were scheduled on Days 1, 2, 29, 57, 84, and
85. On Days 1, 29, 57, and 84, FEV1 was assessed at 50
Feldman et al. BMC Pulmonary Medicine 2010, 10:11
http://www.biomedcentral.com/1471-2466/10/11
Page 2 of 9and 15 min pre-dose and 5 and 30 min after dose
administration in the clinics. On Days 1 and 84, besides
the above-mentioned time points, FEV1 was also
assessed at 1, 2, and 4 h post-dose. Trough FEV1 (at 23
h 10 min and 23 h 45 min after the previous day’s dose)
was measured on Days 2 and 85. Spirometry equipment
calibration and spirometric testing were performed in
accordance with American Thoracic Society/European
Respiratory Society standards [13].
Patients were given a diary to record morning and
evening peak expiratory flow (PEF; highest of three con-
secutive efforts), daily clinical symptoms, rescue salbuta-
mol use, any change in concomitant medications, and
adverse events (AEs). Diaries were to be completed at
the same time in the morning (before taking study
drug) and in the evening (approximately 12 h later).
Safety assessments included recording of AEs and ser-
ious AEs (SAEs) and monitoring of haematology and
blood chemistry (including serum potassium and blood
glucose), vital signs, and electrocardiograms including
QTc interval (Fridericia’s correction). A COPD exacer-
bation was defined as a new onset or worsening of more
than one respiratory symptom (i.e., dyspnoea, cough,
sputum purulence or volume, or wheeze) present for
more than 3 consecutive days plus either a documented
change or increase in COPD-related treatment due to
worsening symptoms (e.g., steroids/antibiotics/oxygen),
or documented COPD-related hospitalizations or emer-
gency room visits.
Variables assessed
The primary efficacy variable was trough FEV1 after 12
weeks of treatment (average of the 23 h 10 min and 23
h 45 min post-dose values assessed on the morning of
Day 85). The secondary efficacy variables included
trough FEV1 after one dose (assessed pre-dose on Day
2) and after 29 days, individual time point FEV1 on Day
1 and at Week 12 (change from baseline), peak FEV1 on
Day 1 and at Week 12 (assessed between 5 min and 4 h
post-dose), and standardised area under the curve
(AUC) for FEV1 between 5 min and 4 h, 5 min and 1 h,
and 1 h and 4 h at Week 12.
Other efficacy outcomes were based on data recorded
on patients’ diaries. These included use of rescue medica-
t i o n ,P E F ,a n dt h en u m b e ro f‘days of poor control’,
defined as any day in the patient diary in which a score ≥2
(i.e., moderate or severe symptoms) was recorded for at
least two out of five symptoms (cough, wheeze, production
of sputum, colour of sputum, and breathlessness). This
instrument has not been validated, although it was used
previously in the Foradil registration programme [4,6].
Sample size and statistical analyses
A difference of 120 mL in trough FEV1 between indaca-
terol and placebo was pre-specified as the minimal
clinically important difference for this population. A
standard deviation of 270 mL was assumed for trough
FEV1, based on the results from previous formoterol
studies [6,8]. It was calculated that, allowing for a poten-
tial imbalance between treatment groups, a sample size
of 232 evaluable patients would be needed to test for
the minimal clinically important difference of 120 mL
between indacaterol 150 μg and placebo at the (two-
sided) 5% significance level with 90% power. Allowing
for a drop-out rate of 20%, it was estimated that a mini-
mum of 290 patients were needed to provide 90%
power for the primary endpoint.
All efficacy analyses were performed on the intent-to-
treat (ITT) population, which included all patients who
were randomised to receive treatment. All safety ana-
lyses were performed on the safety population, which
included all patients who received at least one dose of
the study medication.
A mixed model was used to analyse the primary vari-
able (imputed with last observation carried forward)
with treatment as a fixed effect and the baseline FEV1
and FEV1 reversibility components as covariates. The
model also included smoking status (current/ex-smoker)
and country as fixed effects, with centre nested within
country as a random effect. The least squares means
(LSM), i.e., means adjusted for the covariates in the
model, of the treatment contrast for indacaterol 150 μg
versus placebo was estimated along with the associated
95% confidence interval and two-sided p-value, and
superiority of indacaterol over placebo was demon-
strated only if the p-value was less than the pre-specified
5% significance level.
Results
Patients
This study was conducted at 103 centres in 3 countries
(US, New Zealand and Belgium). A total of 788 patients
were screened, with 416 randomised to either indaca-
terol 150 μg (n = 211) or placebo (n = 205). Overall,
364 patients (87.5%) completed the study, (Figure 1).
Both treatment groups were comparable and well
matched with respect to baseline demographic and dis-
ease characteristics (Table 1); 52.4% of patients were
male and 92.5% were Caucasian. The mean duration of
COPD was 6.9 years, with diagnosis status ranging from
newly diagnosed to 38.7 years of disease history.
Almost all randomised patients (99.0%) had at least
one active medical condition, the most common being
hypertension (51.4%), gastro-oesophageal reflux (30.0%),
depression (23.8%), osteoarthritis (22.4%), and hyperlipi-
daemia (21.6%). Mean patient exposures to study medi-
cation were similar between treatment groups (85.0 and
84.0 days for indacaterol and placebo, respectively), and
compliance was high in both groups (>97%).
Feldman et al. BMC Pulmonary Medicine 2010, 10:11
http://www.biomedcentral.com/1471-2466/10/11
Page 3 of 9Efficacy
Spirometry evaluations
For the primary endpoint, that is, 24-h post-dose trough
FEV1 at Week 12, indacaterol provided a bronchodilator
efficacy superior to that of placebo, with an LSM ± stan-
dard error of the mean (SEM) indacaterol-placebo dif-
ference of 130 ± 24 mL (p < 0.001), which exceeded the
120 mL threshold for clinical relevance (Figure 2). Inda-
caterol also provided statistically superior efficacy to pla-
cebo for 24-h post-dose trough FEV1 after the first dose,
with a difference from placebo of 80 ± 19 mL (p <
0.001) (Figure 2). On Day 29, the indacaterol-placebo
difference was 140 ± 24 mL (p < 0.001).
Individual time-point FEV1 (mean change from base-
line) over the first 4 h post-dose on Day 1 and at Week
12 are shown in Figure 3. At all post-baseline time
points, indacaterol provided statistically superior FEV1
to that of placebo (p < 0.001). At the first post-baseline
time point assessed (5 min post-dose on Day 1), the
LSM ± SEM indacaterol-placebo difference was 130 ±
15 mL (p < 0.001).
Indacaterol 150 μg o.d. was associated with significantly
higher peak FEV1 than placebo, both on Day 1 and at
Week 12, with LSM ± SEM indacaterol-placebo differ-
ences of 190 ± 28 mL (p < 0.001) and 160 ± 28 mL (p <
0.001), respectively. Furthermore, standardised AUC mea-
surements for FEV1 (between 5 min and 4 h, 5 min and
1 h, and 1 and 4 h post-dose) at Week 12 were all signifi-
cantly greater with indacaterol 150 μg as compared with
placebo (p < 0.001), with LSM differences of 170 ± 24 mL,
180 ± 24 mL, and 170 ± 24 mL, respectively (Table 2).
Patient diary evaluations
Patients were asked to use their diaries twice daily to
record their PEF, rescue medication use, and symptoms.
Figure 1 Patient disposition.
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in both morning and evening PEF were significantly
greater for indacaterol 150 μg versus placebo, with LSM ±
SEM improvements versus placebo of 24.6 ± 3.18 and
23.6 ± 3.11 L/min in morning and evening PEF, respec-
tively (both, p < 0.001). In addition, patients taking indaca-
terol 150 μg o.d. required significantly less rescue
medication compared with patients on placebo, as mea-
sured by mean daily, daytime, and night-time number of
puffs of rescue medication (all, p < 0.001), with a signifi-
cant improvement in the percentage of days with no res-
cue use (p < 0.001; Table 3). The percentage of COPD
‘days of poor control’ over 12 weeks of treatment (defined
in the Methods section) was 22.5% lower in the indaca-
terol 150 μg o.d. treatment group compared with the pla-
cebo group (p < 0.001; Table 3).
Safety
The overall rate of AEs was comparable between the two
treatment groups (Table 4). The most frequently
reported AEs in the indacaterol and placebo groups by
preferred term were COPD worsening (including exacer-
bations; 8.5% and 12.2%, respectively) and cough (6.2%
and 7.3%, respectively). The incidences of AEs known to
be b2-agonist class effects (muscle spasm, headache, and
tremor) were comparable between the indacaterol and
placebo groups. Most of the AEs observed were of mild
or moderate intensity; severe AEs occurred in 4.7% of
indacaterol-treated patients versus 5.4% of placebo-trea-
ted patients. AEs suspected to be related to study drug
occurred in a similar proportion of patients in the two
treatment groups (8.1% in the indacaterol vs. 7.8% in the
placebo group). One patient in the placebo group died
during the study (female, 51 years). The cause of death
was unknown at the time but was suspected to be related
to study medication by the sponsor’s medical safety phy-
sician in the absence of the investigator’s causality assess-
ment. However, an autopsy suggested that the cause of
death was cardiac arrhythmia due to cardiomegaly, and
the investigator assessed the event as not related to study
Table 1 Patient demographic and baseline clinical
characteristics (safety population)
Indacaterol
150 μg o.d.
N = 211
Placebo
N = 205
Age, in years, mean (SD) 62.9 (9.89) 63.2 (9.62)
Sex, n (%)
Male 108 (51.2) 110 (53.7)
Female 103 (48.8) 95 (46.3)
Race, n (%)
Caucasian 194 (91.9) 191 (93.2)
Black 12 (5.7) 10 (4.9)
Asian 1 (0.5) 1 (0.5)
Native American 2 (0.9) 1 (0.5)
Other 2 (0.9) 2 (1.0)
Duration of COPD, in years, mean (SD) 6.6 (6.86) 7.3 (5.64)
Duration of COPD, in years, n (%)
<1 38 (18.0) 18 (8.8)
1—5 74 (35.1) 69 (33.7)
>5—10 57 (27.0) 69 (33.7)
>10—15 23 (10.9) 30 (14.6)
>15—20 9 (4.3) 12 (5.9)
>20 10 (4.7) 7 (3.4)
Severity of COPD*, n (%)
At risk 0 (0.0) 1 (0.5)
Mild 7 (3.3) 10 (4.9)
Moderate 119 (56.4) 117 (57.1)
Severe 84 (39.8) 76 (37.1)
Very severe 1 (0.5) 1 (0.5)
Smoking history, n (%)
Ex-smoker 103 (48.8) 97 (47.3)
Current smoker 108 (51.2) 108 (52.7)
Number of pack years
†, mean (SD) 53.5 (26.84) 60.5 (54.12)
FEV1 (L), mean (SD)
‡ 1.5 (0.53) 1.5 (0.51)
FEV1 (% predicted), mean (SD)
‡ 54.4 (13.38) 55.8 (14.08)
FEV1/FVC (%), mean (SD)
‡ 53.5 (9.84) 53.5 (10.36)
FEV1 reversibility (%), mean (SD) 16.4 (17.31) 16.6 (19.44)
Concomitant ICS, n (%) 61 (28.9) 70 (34.1)
COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory
volume in 1 s; FVC = forced vital capacity; ICS = inhaled corticosteroids.
*As per GOLD 2005
†Pack years = total years of smoking multiplied by cigarette packs smoked per
day
‡Post-bronchodilator (within 30 min after inhaling 400 μg salbutamol)
Figure 2 24-h post-dose (trough) FEV1 after 1 day and at Week
12 of treatment (ITT population). Data are LSM ± SEM. Significant
treatment difference: ***p < 0.001 versus placebo. FEV1 = forced
expiratory volume in 1 s; ITT = intent-to-treat; LSM = least squares
means; SEM = standard error of mean.
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sidered to be related to study medication.
Investigators were also asked to record any instances
of cough occurring within 5 min of drug administration
during study visits, regardless of whether they consid-
ered this to be an AE. This was observed at clinic visits
with an average incidence of 17.8% with indacaterol and
3.3% with placebo. The onset of cough following inhala-
tion was predominantly within 15 s of inhalation, with
Figure 3 Individual time-point FEV1 on Day 1 and at Week 12 (change from baseline, ITT population). Individual time-point FEV1 (A) on
Day 1 (baseline to 4 h) and (B) at Week 12 (-50 min to +4 h). FEV1 = forced expiratory volume in 1 s; ITT = intent-to-treat.
Table 2 Standardised AUC for FEV1 at Week 12:
treatment comparisons (ITT population)
Treatment Treatment difference
LSM ± SEM LSM ± SEM
AUC(5 min—4h )for FEV1
Indacaterol 150 μg o.d. 1.54 ± 0.019
0.17 ± 0.024*
Placebo 1.37 ± 0.020
AUC(5 min—1h )for FEV1
Indacaterol 150 μg o.d. 1.52 ± 0.020
0.18 ± 0.024*
Placebo 1.34 ± 0.020
AUC(1 h—4h )for FEV1
Indacaterol 150 μg o.d. 1.55 ± 0.020
0.17 ± 0.024*
Placebo 1.37 ± 0.021
*p < 0.001
AUC = area under the curve; FEV1 = forced expiratory volume in 1 s; ITT =
intent-to-treat; LSM = least squares mean; SEM = standard error of mean
Table 3 Rescue medication use and percentage of COPD
‘days of poor control’ over 12 weeks of treatment (ITT
population)
Treatment Treatment difference
Treatment LSM ± SEM LSM ± SEM
Change from baseline in the mean daily number of puffs of rescue
medication
Indacaterol 150 μg o.d. -1.38 ± 0.118
-0.97 ± 0.168*
Placebo -0.41 ± 0.122
Change from baseline in the mean day time number of puffs of
rescue medication
Indacaterol 150 μg o.d. -0.92 ± 0.076
-0.65 ± 0.109*
Placebo -0.27 ± 0.079
Change from baseline in the mean night time number of puffs of
rescue medication
Indacaterol 150 μg o.d. -0.47 ± 0.052
-0.34 ± 0.075*
Placebo -0.13 ± 0.054
Percentage of days with no rescue use
Indacaterol 150 μg o.d. 54.63 ± 1.942
13.35 ± 2.791*
Placebo 41.28 ± 2.004
Percentage of COPD ‘days of poor control’
Indacaterol 150 μg o.d. 31.19 ± 1.500
-9.05 ± 2.175*
Placebo 40.24 ± 1.554
COPD = chronic obstructive pulmonary disease; ITT = intent-to-treat;
LSM = least squares mean; SEM = standard error of the mean
* p < 0.001
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between cough and bronchospasm. Importantly, the pre-
sence of this cough was not associated with any increase
in study discontinuation rates.
Laboratory evaluations (including blood glucose and
serum potassium) showed no clinically relevant differ-
ences between the indacaterol 150 μg and placebo
groups. No patient had a clinically notable low potas-
sium value (i.e., <3.0 mmol/L), while the proportion of
patients with clinically notable hyperglycaemia (>9.99
mmol/L) was lower in the indacaterol group than in the
placebo group (3.3% vs. 6.3%).
The percentage of patients who had a maximum post-
baseline pulse rate >90 bpm at any visit was lower in
the indacaterol group as compared with the placebo
group (5.7% vs. 11.2%), and no patients in either group
experienced either a pulse rate >130 bpm or a pulse rate
≥1 2 0b p mw i t hac h a n g ef r o mb a s e l i n e≥15 bpm. No
patients in the indacaterol group experienced a maxi-
mum post-baseline systolic blood pressure >200 mmHg,
or ≥180 mmHg with an increase from baseline ≥20
mmHg (compared with one patient receiving placebo);
one patient in the indacaterol group (compared with
none in the placebo group) had a maximum post-base-
line diastolic blood pressure ≥105 mmHg with an
increase from baseline ≥15 mmHg. The number of
patients with a notable maximum post-baseline QTc
interval (Fridericia’s; i.e., >450 ms for males or >470 ms
for females) was 7 (3.3%) in the indacaterol versus 4
(2.0%) in the placebo group. No patient in either group
had a QTc interval (Fridericia’s) >500 ms and none had
an increase from baseline in QTc interval of >60 ms.
Discussion
This study was designed to assess the 12-week efficacy
and safety of indacaterol 150 μg o.d. in patients with
moderate-to-severe COPD. Significant bronchodilation
was observed following administration of the first dose
of indacaterol, with efficacy sustained over the full 12-
week treatment period. Trough FEV1 after 12 weeks of
treatment (the primary endpoint) exceeded the placebo
value by more than 120 mL (the pre-specified minimum
clinically important difference). This value of 120 mL is
higher than the 100 mL described by Donohue as a dif-
ference that patients can perceive [14] and is the mid-
point of the 100-140 mL range proposed recently as a
minimal clinically important difference [15]. A statisti-
cally superior improvement in FEV1 for indacaterol
versus placebo was also observed at all individual post-
baseline time points on Day 1 and Week 12, with
improvements versus placebo for FEV1 AUCs between 5
m i na n d1h ,5m i na n d4h ,a n d1a n d4hp o s t - d o s e .
These results demonstrate a sustained 24-h duration of
action of indacaterol on o.d. dosing. This persistence of
treatment effect has also been observed in other
published indacaterol studies [9-11], including a double-
blind crossover study in patients with moderate-to-
severe COPD, in which a single dose of indacaterol 150
μg provided comparable 24-h trough FEV1 to twice-
daily formoterol [11].
Although a sustained 24-h effect is advantageous in
the treatment of COPD patients, it is important that
this is not accompanied by a loss in efficacy on chronic
dosing (or tolerance). b2-adrenoceptor downregulation
following chronic dosing with LABAs may result in the
development of tolerance to the bronchodilatory effects
of LABAs [16], and previous studies have shown the
diminution in efficacy over time in other bronchodila-
tors, including salmeterol [17]. The results of our study
demonstrate that there was no loss in efficacy over the
12 weeks of treatment, with indacaterol-placebo differ-
ences maintained from Day 29 (the first trough assess-
ment after indacaterol is known to have reached steady-
state) to Week 12 in terms of trough FEV1. These data
are consistent with other previously published studies
with indacaterol, in which there was no loss in efficacy
on daily dosing for up to a year. For example, in a
1-year study, the trough FEV1 for indacaterol 150 μg
was 160 mL higher than placebo after 12 weeks of dos-
ing, compared with 170 mL after a year [18].
In the current study, serial measurements of FEV1 on
Day 1 also showed that indacaterol 150 μgo . d .p r o v i d e d
statistically significant (compared to placebo) and clinically
relevant bronchodilation at 5 min post-dose, the earliest
post-dose assessment time point in this study, and is con-
sistent with previous studies [10,11]. The o.d. dosing
Table 4 Adverse events (including COPD exacerbations)
overall and by primary system organ class (>3% in either
treatment group; Safety population)
Indacaterol
150 μg o.d.
N = 211
n (%)
Placebo
N = 205
n (%)
Patients with any adverse event (s) 104 (49.3) 96 (46.8)
Primary system organ class
Respiratory, thoracic and mediastinal disorders 40 (19.0) 43 (21.0)
Infections and infestations 37 (17.5) 28 (13.7)
Gastrointestinal disorders 19 (9.0) 14 (6.8)
Musculoskeletal and connective tissue
disorders
16 (7.6) 17 (8.3)
Nervous system disorders 11 (5.2) 11 (5.4)
General disorders and administration site
conditions
9 (4.3) 10 (4.9)
Injury, poisoning and procedural complications 9 (4.3) 5 (2.4)
Investigations 7 (3.3) 7 (3.4)
COPD = chronic obstructive pulmonary disease
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bronchodilation at 5 min post-dose may contribute to
improved adherence to the prescribed dose regimen in the
‘real world’ setting—an important consideration, because
adherence to COPD medication in clinical practice are
reported to be between 10 and 40% [19-21].
Alongside the improvements in FEV1, indacaterol also
provided improvements compared with placebo in terms
of a range of data captured by patients in their daily dia-
ries, including significant improvements from baseline in
morning and evening PEF, and reductions in the
requirement for rescue medication. The frequency of
use of rescue medication for symptomatic relief provides
an indication of the degree of patient impairment. It is,
therefore, of note that the use of indacaterol was asso-
ciated with an overall reduction in rescue medication
use, with improvements observed both in daytime and
night-time over a 24-h dosing interval.
Indacaterol 150 μg o.d. was well tolerated, with a high
level of treatment compliancea n dal o wd r o p - o u tr a t e .
The overall incidence of AEs was comparable between
indacaterol and placebo, and AEs were mostly mild and
transient, with the majority being typical of this patient
population. The most frequently reported AEs were
COPD worsening and cough, the incidences of which
were lower in the indacaterol group than placebo. The
presence of cough following soon after inhalation was
not associated with any increase in study discontinua-
tion rates, and there was no suggestion of a relationship
between these cough events and cough reported as an
AE. The class-related side effects of b2-agonists (e.g.,
hyperglycaemia, hypokalaemia, or prolonged QTc inter-
val) were low in overall incidence in this study. No
patient had a clinically notable low potassium value (i.e.
<3.0 mmol/L), while clinically notable hyperglycaemia
(>9.99 mmol/L) occurred in fewer patients in the inda-
caterol group than in the placebo group. No patient in
either group had an absolute QTc interval (Fridericia’s)
of greater than 500 ms, and none had an increase in
Q T cf r o mb a s e l i n eo fm o r et h a n6 0m s .C a r d i a cs a f e t y
is of particular concern in COPD patients considering
the fact that cardiovascular comorbidity is common in
these patients; therefore, the absence of detrimental car-
diovascular incidents in this study, together with results
from earlier shorter-duration studies, suggest that the
risk of adverse cardiovascular effects with indacaterol
150 μg is low [9-11]. Moreover, data from other studies
have shown similar safety findings with single doses of
up to 3000 μg [22].
Conclusions
Indacaterol 150 μg o.d. showed effective bronchodilation
in patients with moderate-to-severe COPD, with a sig-
nificantly reduced rescue medication use compared with
placebo. Our results suggest that indacaterol may pre-
sent a useful alternative to the currently available twice-
daily LABAs, given the sustained 24-h bronchodilation
on o.d. dosing.
Note
†INdacaterol efficacy evaLuation usInG 150 μgd o s e s
witH COPD paTients 1
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